Home » RITUXAN RECEIVES EXPANDED INDICATION
RITUXAN RECEIVES EXPANDED INDICATION
The FDA has approved an expanded indication for Genentech's cancer drug Rituxan (rituximab). The indication is for a first-line treatment of diffuse large B-cell, CD20+, non-Hodgkin's lymphoma, in combination with CHOP or other anthracycline-based chemotherapy regimens.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
07May
-
14May
-
23May
-
30May
-
20Jun
-
21Oct